Genomic Vision to Enter into Technological Collaboration with AstraZeneca in Oncology

The FiberVision® platform will test the impact of a WEE1 kinase inhibitor on DNA replication in cancer cells.

BAGNEUX, France--()--Regulatory News:

Genomic Vision (Paris:GV) (FR0011799907 – GV), a company specialized in the development of diagnostic tests (IVD) for the early detection of cancers and genetic diseases and applications for life sciences research (LSR), today announced that they have entered into a technological collaboration with AstraZeneca in the field of targeting DNA damage response (DDR) for novel anti-cancer treatments strategy.

Through the use of FiberVision®, the DNA molecular combing platform of Genomic Vision, AstraZeneca will evaluate the impact of the WEE1 kinase inhibitor on DNA replication progression in cancer cells and how the induction of replication stress contributes to its anti-tumour efficacy in specific cancer genetic backgrounds.

Molecular combing should allow a comprehensive characterisation of the different replication stress effects induced by the WEE1 inhibitors. Wider profiling using the platform will also be carried out to enable mechanistic differentiation between DDR inhibitors within the AstraZeneca portfolio. The in-depth scientific understanding of replication stress obtained by the innovative molecular combing platform could support the development of new personalised medicine opportunities for DDR inhibitors.

Aaron Bensimon, CEO of Genomic Vision, declared: “This collaboration agreement on the use of the molecular combing by AstraZeneca, one of the most innovative companies in the research of novel anti-cancer agents, represents a strong recognition of our technology added value. Initially used for the development of diagnostic tests, molecular combing indeed offers substantial outlooks to accelerate the selection and optimization process of high potential therapeutic compounds for the treatment of cancer.”

ABOUT GENOMIC VISION

GENOMIC VISION is a company specialized in the development of diagnostic solutions for the early detection of cancers and serious genetic diseases and tools for life sciences research. Through the DNA Molecular Combing, a strong proprietary technology allowing to identify genetic abnormalities, GENOMIC VISION stimulates the R&D productivity of the pharmaceutical companies, the leaders of the diagnostic industry and the research labs. The Company develops a robust portfolio of diagnostic tests (breast, ovarian and colorectal cancers, myopathies) and analysis tools (DNA replication, biomarkers discovery, gene editing quality control). Based near Paris, in Bagneux, the Company has approximately 60 employees. GENOMIC VISION is a public listed company listed in compartment C of Euronext’s regulated market in Paris (Euronext: GV - ISIN: FR0011799907). For further information, please visit www.genomicvision.com

Member of CAC® Mid & Small and CAC® All-Tradable indexes

FORWARD LOOKING STATEMENT

This press release contains implicitly or explicitly certain forward-looking statements concerning Genomic Vision and its business.

Such forward-looking statements are based on assumptions that Genomic Vision considers to be reasonable. However, there can be no assurance that such forward-looking statements will be verified, which statements are subject to numerous risks, including the risks set forth in the “Risk Factors” section in its Document de Reference filed with the French Autorité des Marchés Financiers (AMF) on March 28, 2017, under number R.17-009, available on the web site of Genomic Vision (www.genomicvision.com) and to the development of economic conditions, financial markets and the markets in which Genomic Vision operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Genomic Vision or not currently considered material by Genomic Vision. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Genomic Vision to be materially different from such forward-looking statements.

This press release and the information contained herein do not constitute and should not be construed as an offer or an invitation to sell or subscribe, or the solicitation of any order or invitation to purchase or subscribe for Genomic Vision shares in any country. The distribution of this press release in certain countries may be a breach of applicable laws. The persons in possession of this press release must inquire about any local restrictions and comply with these restrictions.

Contacts

Genomic Vision
Aaron Bensimon
Co-founder, Chairman & CEO
Tel. : +33 1 49 08 07 50
investisseurs@genomicvision.com
or
Milestones
Press Relations
Bruno Arabian
Tel. : +33 1 83 62 34 84
barabian@milestones.fr
or
NewCap
Investor Relations
Dušan Orešanský / Emmanuel Huynh
Tel. : +33 1 44 71 94 92
gv@newcap.eu

Release Summary

Genomic Vision to enter into technological collaboration with AstraZeneca in oncology

Contacts

Genomic Vision
Aaron Bensimon
Co-founder, Chairman & CEO
Tel. : +33 1 49 08 07 50
investisseurs@genomicvision.com
or
Milestones
Press Relations
Bruno Arabian
Tel. : +33 1 83 62 34 84
barabian@milestones.fr
or
NewCap
Investor Relations
Dušan Orešanský / Emmanuel Huynh
Tel. : +33 1 44 71 94 92
gv@newcap.eu